



OHIO DEPARTMENT OF MEDICAID

Pharmacy & Therapeutics Committee

Public attendees will need to register at:

<https://attendee.gotowebinar.com/register/6996645897747704335>

After registering, you will receive an email containing information about joining the webinar.

January 13th, 2021

10:00 A.M.

AGENDA

- I. Call to Order
- II. Introductions
- III. Approval of September 30, 2020 Meeting Minutes
- IV. Administrative Matters
 - A. Conflict of Interest Statements
- V. Department of Medicaid Update
- VI. Interested Party Presentations
- VII. Unified Preferred Drug List (UPDL) Proposals
 - A. Central Nervous System (CNS) Agents: Anticonvulsants
 - Fintepla (fenfluramine HCl solution), Zogenix, Inc.
 - B. Central Nervous System (CNS) Agents: Multiple Sclerosis
 - Bafiertam (monomethyl fumarate capsule), Banner Life Sciences LLC
 - Kesimpta (ofatumumab injection), Novartis
 - C. Central Nervous System (CNS) Agents: Parkinson's Agents
 - Ongentys (opicapone capsule), Neurocrine Biosciences, Inc.
 - D. Endocrine Agents: Diabetes – Insulin
 - Semglee (insulin glargine injection), Mylan
 - E. Gastrointestinal Agents: Ulcerative Colitis Agents
 - Ortikos ER (budesonide capsule), Ferring Pharmaceuticals Inc
 - F. Infectious Disease Agents: Antivirals – HIV
 - Rukobia ER (fostemsavir tablet), ViiV Healthcare Company
 - G. Respiratory Agents: Inhaled Agents
 - Airduo Digihaler (fluticasone and salmeterol), Teva Respiratory, LLC
 - Armonair Digihaler (fluticasone propionate), Teva Respiratory, LLC
 - Breztri™ (budesonide, glycopyrrolate and formoterol), AstraZeneca Pharmaceuticals LP
- VIII. Other Business
- IX. 2021 Meeting Dates
 - A. Quarter 2 – Wednesday, April 14, 2021
 - B. Quarter 3 – Wednesday, July 14, 2021
 - C. Quarter 4 – Wednesday, October 6, 2021
- X. Adjournment